PMID- 23313572 OWN - NLM STAT- MEDLINE DCOM- 20130923 LR - 20211021 IS - 1089-8611 (Electronic) IS - 1089-8603 (Print) IS - 1089-8603 (Linking) VI - 30 DP - 2013 Apr 1 TI - Hemoglobin infusion does not alter murine pulmonary vascular tone. PG - 1-8 LID - S1089-8603(13)00003-7 [pii] LID - 10.1016/j.niox.2012.12.007 [doi] AB - Plasma hemoglobin (Hb) scavenges endothelium-derived nitric oxide (NO), producing systemic and pulmonary vasoconstriction in many species. We hypothesized that i.v. administration of murine cell-free Hb would produce pulmonary vasoconstriction and enhance hypoxic pulmonary vasoconstriction (HPV) in mice. To assess the impact of plasma Hb on basal pulmonary vascular tone in anesthetized mice we measured left lung pulmonary vascular resistance (LPVRI) before and after infusion of Hb at thoracotomy. To confirm the findings obtained at thoracotomy, measurements of right ventricular systolic pressure (RVSP) and systemic arterial pressure (SAP) were obtained in closed-chest wild-type mice. To elucidate whether pretreatment with Hb augments HPV we assessed the increase in LPVRI before and during regional lung hypoxia produced by left mainstem bronchial occlusion (LMBO) in wild-type mice pretreated with Hb. Infusion of Hb increased SAP but did not change pulmonary arterial pressure (PAP), left lung pulmonary arterial flow (QLPA) or LPVRI in either wild-type or diabetic mice with endothelial dysfunction. Scavenging of NO by plasma Hb did not alter HPV in wild-type mice. Inhibition of NO synthase with l-NAME did not change the basal LPVRI, but augmented HPV during LMBO. Our data suggest that scavenging of NO by plasma Hb does not alter pulmonary vascular tone in mice. Therefore, generation of NO in the pulmonary circulation is unlikely to be responsible for the low basal pulmonary vascular tone of mice. CI - Copyright (c) 2013 Elsevier Inc. All rights reserved. FAU - Beloiartsev, Arkadi AU - Beloiartsev A AD - Postdoctoral Fellow, Anesthesia Center for Critical Care Research of the Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114-2696, USA. FAU - Baron, David M AU - Baron DM FAU - Yu, Binglan AU - Yu B FAU - Bloch, Kenneth D AU - Bloch KD FAU - Zapol, Warren M AU - Zapol WM LA - eng GR - R01 HL074352/HL/NHLBI NIH HHS/United States GR - HL074352/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20130108 PL - United States TA - Nitric Oxide JT - Nitric oxide : biology and chemistry JID - 9709307 RN - 0 (Hemoglobins) RN - 0 (Vasoconstrictor Agents) RN - 11062-77-4 (Superoxides) RN - 31C4KY9ESH (Nitric Oxide) RN - 76898-47-0 (15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid) RN - EC 1.14.13.39 (Nitric Oxide Synthase) RN - V55S2QJN2X (NG-Nitroarginine Methyl Ester) SB - IM MH - 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid/pharmacology MH - Analysis of Variance MH - Animals MH - Blood Pressure/drug effects MH - Diabetes Mellitus, Experimental MH - Hemoglobins/*administration & dosage MH - Hypoxia MH - Lung/*blood supply/chemistry/*drug effects/metabolism MH - Male MH - Mice MH - Mice, Inbred C57BL MH - NG-Nitroarginine Methyl Ester/metabolism MH - Nitric Oxide/metabolism MH - Nitric Oxide Synthase/metabolism MH - Superoxides/metabolism MH - Thoracotomy MH - Vascular Resistance/*drug effects MH - Vasoconstriction/*drug effects MH - Vasoconstrictor Agents/pharmacology PMC - PMC3764648 MID - NIHMS504089 EDAT- 2013/01/15 06:00 MHDA- 2013/09/24 06:00 PMCR- 2014/04/01 CRDT- 2013/01/15 06:00 PHST- 2012/11/21 00:00 [received] PHST- 2012/12/18 00:00 [revised] PHST- 2012/12/28 00:00 [accepted] PHST- 2013/01/15 06:00 [entrez] PHST- 2013/01/15 06:00 [pubmed] PHST- 2013/09/24 06:00 [medline] PHST- 2014/04/01 00:00 [pmc-release] AID - S1089-8603(13)00003-7 [pii] AID - 10.1016/j.niox.2012.12.007 [doi] PST - ppublish SO - Nitric Oxide. 2013 Apr 1;30:1-8. doi: 10.1016/j.niox.2012.12.007. Epub 2013 Jan 8.